Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Atrium Therapeutics (Nasdaq: RNA) granted inducement equity awards on July 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan. The awards comprise options for 7,000 shares at $11.76 and 3,500 RSUs, each with multi-year vesting tied to continued service.

Market Context

A June 23 inducement-grant announcement was followed by a 0.16% 24-hour reaction. That precedent fra...

Analysis

A June 23 inducement-grant announcement was followed by a 0.16% 24-hour reaction. That precedent frames today's award as a recurring compensation event; vesting terms and moderate short positioning are the key watchpoints.

Key Figures

Grant Date: July 20, 2026 Stock Options: 7,000 shares Par Value: $0.001 per share +5 more

8 metrics

Grant Date July 20, 2026 Inducement awards

Stock Options 7,000 shares Non-qualified stock options

Par Value $0.001 per share Common stock

Exercise Price $11.76 per share Stock options

Initial Vesting 25% Options after the first anniversary

Monthly Vesting 36 installments Remaining option shares

Restricted Stock Units 3,500 shares Aggregate RSU award

Annual Vesting 3 installments Remaining RSU shares

Historical Context

5 past events · Latest: Jul 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 14	FDA clearance	Positive	+0.0%	FDA cleared IND application for ATR 1072 and enabled Phase 1/2 trial initiation
Jun 23	Inducement grants	Negative	+0.2%	Equity awards granted to eight newly hired non-executive employees
May 14	Quarterly earnings	Negative	-0.3%	Quarterly results included a net loss despite collaboration revenue and milestone income
Apr 23	Milestone payment	Positive	+1.4%	Bristol Myers Squibb collaboration generated a $15 million development milestone
Apr 20	Inducement grants	Negative	-5.4%	Equity awards granted to seven newly hired non-executive employees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Inducement-grant announcements produced mixed 24-hour reactions, ranging from -5.38% to +0.16%; the FDA-clearance event had a 0% reaction.

Key Terms

non-qualified stock options, restricted stock units, inducement grants, Nasdaq Listing Rule 5635(c)(4)

4 terms

non-qualified stock options financial

"The employee received, in the aggregate, non-qualified stock options"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units for an aggregate of 3,500 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement grants financial

"today announced it awarded inducement grants on July 20, 2026"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

The employee received, in the aggregate, non-qualified stock options to purchase 7,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $11.76 per share, the closing price of the Company's common stock as reported by Nasdaq on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 3,500 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in 3 substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards."

All of the above-described Awards were granted outside of the Company's stockholder-approved equity incentive plans pursuant to the 2026 Inducement Plan, which was adopted by the Company's board of directors (the "Board") in April 2026. The Awards were approved by the Board's Human Capital Management Committee, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atrium Therapeutics

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to the skeletal muscle and applies it for efficient delivery to the heart with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.

For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302830029.html

SOURCE Atrium Therapeutics

FAQ

What inducement equity awards did Atrium Therapeutics (RNA) grant on July 20, 2026?

Atrium Therapeutics granted stock options for 7,000 shares and 3,500 restricted stock units to one newly hired non-executive employee. According to Atrium Therapeutics, these inducement awards were issued under the 2026 Employment Inducement Incentive Award Plan in connection with the employee’s commencement of employment.

What is the exercise price of the July 20, 2026 Atrium Therapeutics (RNA) inducement stock options?

The inducement stock options have an exercise price of $11.76 per share, matching the Nasdaq closing price on the grant’s effective date. According to Atrium Therapeutics, the employee can purchase up to 7,000 shares at this fixed exercise price, subject to vesting and continued service.

How do the Atrium Therapeutics (RNA) inducement stock options granted in July 2026 vest?

The inducement stock options vest 25% on the first anniversary of the July 20, 2026 grant date. According to Atrium Therapeutics, the remaining shares vest in 36 substantially equal monthly installments thereafter, conditioned on the employee’s continued service through each applicable vesting date.

What is the vesting schedule for the 3,500 Atrium Therapeutics (RNA) inducement RSUs granted in July 2026?

The 3,500 RSUs vest 25% on the first anniversary of the grant date, then annually in three equal installments. According to Atrium Therapeutics, each vesting tranche requires the employee’s continued service through the relevant vesting date for the underlying shares to be delivered.

Were the July 20, 2026 Atrium Therapeutics (RNA) inducement awards granted under stockholder-approved plans?

The July 20, 2026 awards were granted outside stockholder-approved equity plans, under the 2026 Inducement Plan. According to Atrium Therapeutics, this plan was adopted by the board in April 2026 and used in accordance with Nasdaq Listing Rule 5635(c)(4).